Treatment tailoring based on molecular characterizations

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Dinh, P ^a   Sotiriou, C ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FATTY ACID BINDING PROTEIN; FLUOROURACIL; HOMEODOMAIN PROTEIN; INTERLEUKIN 17 RECEPTOR; LAMININ; PACLITAXEL; PROTEIN P53; TAMOXIFEN; TRANSCRIPTION FACTOR GATA 3; TREFOIL PEPTIDE;

ADJUVANT THERAPY; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CONFERENCE PAPER; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; HUMAN; INDIVIDUALIZATION; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MICROARRAY ANALYSIS; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; ARTICLE; BREAST TUMOR; DNA MICROARRAY; GENETICS; METHODOLOGY; PATHOLOGY; PREDICTION AND FORECASTING;

BREAST NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS;

EID: 53449092794     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn472     Document Type: Conference Paper

References (49)

1. Barrett JC, Kawasaki K. Microarrays: The use of oligonucleotides and cDNA for the analysis of gene expression. Drug Discov Today 2003; 1: 134-141.
2. Kothapalli R, Yoder SJ, Mane S, Loughran TP Jr. Microarray results: How accurate are they? BMC Bioinformatics 2002; 3: 22.
3. Tan PK, Downey TJ, Spitznagel EL Jr et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 2003; 31: 5676-5684.
4. Baum M, Bielau S, Rittner N et al. Validation of a novel, fully integrated and flexible microarray benchtop facility for gene expression profiling. Nucleic Acids Res 2003: 31 e1511.
5. Barczak A, Rodriguez MW, Hanspers K et al. Spoted long oligonucleotide arrays for human gene expression analysis. Genome Res 2003; 13: 1775-1785.
6. Hardiman G. Microarrays technologies 2006: An overview. Pharmacogenomics 2006; 7: 1153-1158.
7. MAOC Consortium. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nature Biotechnol 2006; 24: 1151-1161.
8. Layfield LJ, Goldstein N, Perkinson KR, Proia AD. Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. Breast J 2003; 9: 257-259.
9. Rhodes A, Jasani B, Barnes DM et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000; 53: 125-130.
10. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747-752.
11. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
12. Carey LA, Perou CM, Dressler LG et al. Race and the poor prognosis basal-like breast cancer (BBC) phenotype in the population-based Carolina Breast Cancer Study. J Clin Oncol 2004; (Suppl): (Abstr 9510).
13. Rouzier R, Anderson K, Hess KR. Basal and luminal types of breast cancer defined by gene expression patterns respond differently to neoadjuvant chemotherapy. San Antonio Breast Cancer Symposium. San Antonio, TX 2004; (Abstr 1026).
14. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-10398.
15. Pusztai L, Mazouni C, Anderson K et al. Molecular classification of breast cancer: Limitations and potential. Oncologist 2006; 11: 868-877.
16. Goldhirsh A, Wood WC, Gelber RD et al. Progress and promise: Highlights of the international expert consensus on the pdmary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
17. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
18. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. Nature 2002; 347: 1999-2009.
19. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastases of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679.
20. Foekins JA, Atkins D, Zhang Y et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative pdmary breast cancer. J Clin Oncol 2006; 24: 1665-1671.
21. Buyse M, Loi S, van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-1192.
22. Desmedt C, Piette F, Loi S et al, Strong time-dependency of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multi-centre independent validation series. Fifth European Breast Cancer Conference 2006; late breaking abstract.
23. Paik S, Shak S, Tan G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
24. Paik S, Shak S, Tang G et al. Mufti-gene RT-PCR assay for predicting recurrence in node-negative breast cancer patents - NSABP studies B-20 and B-14. Breast Cancer Research and Treatment 2003; 82 (Suppl 1): S10 (Abstr 16).
25. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262-272.
26. Chang HY, Sneddon JB, Alizadeh AA et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004; 2: E7.
27. Miller LD, Smeds J, George J et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005; 102: 13550-13555.
28. Liu R, Wang X, Chen G et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356: 217-226.
29. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a deathfrom- cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115: 1503-1521.
30. Sotiriou C, Wirapati P, Kunkel S et al. Integrative meta-analysis of geneexpression profiles in breast cancer: Toward a unified understanding of breast cancer sub-typing and prognosis signatures. Breast Cancer Res Treatment 2007; 106 (Suppl 1): S56-S57.
31. Jansen MP, Foekens J, van Staveren IL et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005; 23: 732-740.
32. Ma XJ, Wang Z, Ryan PD et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5: 607-616.
33. Ma XJ, Hilsenbeck SG, Wang W et al. The HOXB13:IL17BR expression index a prognostic factor in early-stage breast cancer. J Clin Oncol 2006; 24: 4611-4619.
34. Jansen MP, Sieuwerts AM, Look MP et al. HOXB13-to-IL17BR expression ratio related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: A retrospective study. J Clin Oncol 2007; 25: 662-668.
35. Oh DS, Troester MA, Usary J et al. Estrogen-regulated genes predict survival hormone receptor-positive breast cancers. J Clin Oncol 2006; 24: 1656-1664.
36. Symanns WF, Hatzis C, Sotiriou C et al. Ability of a 200-gene endocrine sensitivity index (SET) to predict survival for patients who receive adjuvant endocrine therapy or for untreated patients. Proceedings of ASCO 2007; (Abstr 25).
37. Folgueira MA, Carraro DM, Brentani H et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005; 11: 7434-7443.
38. Hannemann J, Oosterkamp HM, Bosch CA et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23: 3331-3342.
39. Chang JC, Wooten EC, Tsimelzon A et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-369.
40. Chang JC, Wooten EC, Tsimelzon A et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005; 23: 1169-1177.
41. Iwao-Koizumi K, Matoba R, Ueno N et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23: 422-431.
42. Bertucci F, Finetti P, Rougemont J et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004; 64: 8558-8565.
43. Andre F, Mazouni C, Hortobagyi GN, Pusztai L. DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design. Biochim Biophys Acta 2006; 1766: 197-204.
44. Rouzier R, Rajan R, Wagner P et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 2005; 102: 8315-8320.
45. Gianni L, Zambetti M, Clark K et al. Gene expression profiles in paraffinembedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23: 7265-77.
46. Hess KR, Anderson K, Symmans WF et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24: 4236-4244.
47. Bild A, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-357.
48. Potti A, Dressman HK, Bild A et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006; 12: 1294-1300.
49. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007; 7: 545-553.